Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk | Zendy

Toshitaka Nakamura | Zendy; Toshitsugu Sugimoto | Zendy; Tetsuo Nakano | Zendy; Hideaki Kishimoto | Zendy; Masako Ito | Zendy; Masao Fukunaga | Zendy; Hiroshi Hagino | Zendy; Teruki Sone | Zendy; Hideki Yoshikawa | Zendy; Yoshiki Nishizawà | Zendy; Takuo Fujita | Zendy; Masataka Shiraki | Zendy

Open Access

Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk

Author(s) -

Toshitaka Nakamura,

Toshitsugu Sugimoto,

Tetsuo Nakano,

Hideaki Kishimoto,

Masako Ito,

Masao Fukunaga,

Hiroshi Hagino,

Teruki Sone,

Hideki Yoshikawa,

Yoshiki Nishizawà,

Takuo Fujita,

Masataka Shiraki

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-3479

Subject(s) - teriparatide , medicine , osteoporosis , placebo , femoral neck , bone mineral , relative risk , randomized controlled trial , bone density , incidence (geometry) , surgery , clinical endpoint , confidence interval , urology , physics , alternative medicine , pathology , optics

Weekly teriparatide injection at a dose of 56.5 μg has been shown to increase bone mineral density.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research